Michelangelo Fiorentino

H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma.

Ricci C, Ambrosi F, Franceschini T, Giunchi F, Maracci ME, Sirolli M, Orsatti A, Chiarucci F, Franchini E, Borsato M, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M.

Pathol Res Pract. 2023 Jan 24. 242:154337. PMID: 36706585

Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.

Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, Mucci LA.

Mol Cancer Res. 2023 Jan 03. 21(1):14-23. PMID: 36125519

Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions.

Gaudiano C, Mottola M, Bianchi L, Corcioni B, Cattabriga A, Cocozza MA, Palmeri A, Coppola F, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Golfieri R, Bevilacqua A.

Cancers (Basel). 2022 Dec 14. 14(24). PMID: 36551642

The prostate stromal transcriptome in aggressive and lethal prostate cancer.

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.

Mol Cancer Res. 2022 Dec 13. PMID: 36511902

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.

Marchese PV, Mollica V, Tassinari E, De Biase D, Giunchi F, Marchetti A, Rosellini M, Fiorentino M, Massari F.

Expert Rev Mol Diagn. 2022 11. 22(11):997-1008. PMID: 36503370

Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma?

Ricci C, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M.

Pathol Res Pract. 2023 Jan. 241:154269. PMID: 36502737

Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap?

Droghetti M, Bianchi L, Beretta C, Balestrazzi E, Costa F, Feruzzi A, Piazza P, Roveroni C, Gaudiano C, Corcioni B, Giunchi F, Fiorentino M, Golfieri R, Schiavina R, Brunocilla E.

World J Urol. 2023 Jan. 41(1):27-33. PMID: 36471133

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.

Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y.

Cancer Discov. 2022 11 02. 12(11):2666-2683. PMID: 35895872

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.

Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altimari A, Gruppioni E, Fiorentino M, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A.

Transl Lung Cancer Res. 2022 Nov. 11(11):2216-2229. PMID: 36519016

A case report of myoid gonadal stromal tumor treated with testis sparing surgery.

Ercolino A, Manes F, Vasuri F, Bianchi L, Garofalo M, Piazza P, Corcioni B, Schiavina R, Golfieri R, Fiorentino M, Colecchia M, Brunocilla E.

Transl Androl Urol. 2022 Oct. 11(10):1458-1465. PMID: 36386257